Introduction
Human venous disease of the lower extremities is a condition affecting millions of people in the world. Its phase of the clinical study are shown in Figure 6 . As in the intraassay comparison, relative differences in VVDs remained constant as the diameters of ectasies increased from the lowest to the highest diameter. Although also in this case there was some variability in VVD measurements, the intermethod agreement was similar to that ob- ferences between subjects cannot be influenced, it is important to reduce, whenever possible, the effect of other factors determining variability.
In the present study by (1) combining the probe with an appropriate spacer that allows imaging of very superficial vessels, (2) performing scans carefully avoiding any contact between the spacer and the patient's skin, and (3) using specific equipment for guiding the operator in patient and probe positioning, we were able to avert biases easily occurring upon repeated measurements.
The ability of the proposed method to assess VVD changes is supported by its capacity to detect changes induced by EG treatment. Data in Figure 8 , indeed, make it clearly evident that the method is sensitive enough to detect, at least in the standing position, VVD changes induced by this pharmacologic treatment. 16 Standing WDs were, in fact, consistently lower after treatment than at baseline, even if differences did not reach statistical significance. Because of the lack of statistical significance, likely due to small sample size, this finding must be viewed with caution; however, the fact that the effects on standing VVD were evident in both phases of the crossover suggests a low probability that results may have been obtained only by chance.
In conclusion, our results show the possibility of measuring WD 
